Preferred Label : Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201;
NCIt synonyms : HPV16 peptides AMPLIVANT Vaccine; PV16 E6 Peptide Conjugated to Amplivant; PV E6 Peptides-Amplivant; SLP HPV16 E6/Amplivant Vaccine ISA201; SLP-Amplivant ISA201; HPV E Six Peptide Conjugated to Amplivant;
NCIt definition : A therapeutic peptide vaccine consisting of two highly immunogenic synthetic long
peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus
(HPV) type 16 oncoprotein E6, and conjugated to a proprietary toll-like receptor 2
(TLR2) ligand (TLR2-L) immunoadjuvant, with potential immunostimulating and antitumor
activities. Upon administration, the TLR2-L moiety of the synthetic long E6 peptides
TLR ligand conjugate vaccine targets and binds to TLRs expressed on antigen-presenting
cells (APCs), particularly dendritic cells (DCs). This increases the direct targeting
of, binding to, uptake by, and processing of the SLPs into small pieces by the DCs.
The processed viral epitopes are presented by DCs, which activate and stimulate the
host immune system to mount specific cytotoxic T-lymphocyte (CTL) and helper T (Th)
cell responses against HPV E6-expressing tumor cells. This results in the destruction
of tumor cells and leads to decreased growth of HPV E6-expressing tumor cells. The
E6 oncoprotein is implicated in tumorigenesis in a variety of cancers. The TLR2-L
improves antigen processing and presentation by, and activation of APCs, thereby improving
the immunostimulatory effect of the vaccine. The two peptides cover the most immunodominant
regions of the HPV16 E6 oncogenic protein and contain both Th and CTL epitopes.;
Drug name : Hespecta;
Molecule name : ISA201;
NCI Metathesaurus CUI : CL512627;
Origin ID : C129652;
UMLS CUI : C4331366;
Semantic type(s)
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
